Back to Search
Start Over
Association between genomic recurrence risk and well-being among breast cancer patients
- Source :
- BMC Cancer, BMC Cancer, 13:295. BioMed Central, BMC cancer, 13:295. BioMed Central Ltd.
- Publication Year :
- 2013
-
Abstract
- Background Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and patients’ well-being. Methods Participants were Dutch women from 10 hospitals being treated for early stage breast cancer who were enrolled in the MINDACT trial (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy). As part of the trial, they received a disease recurrence risk estimate based on a 70-gene signature and on standard clinical criteria as scored via a modified version of Adjuvant! Online. \Women completed a questionnaire 6–8 weeks after surgery and after their decision regarding adjuvant chemotherapy. The questionnaire assessed perceived understanding, knowledge, risk perception, satisfaction, distress, cancer worry and health-related quality of life (HRQoL), 6–8 weeks after surgery and decision regarding adjuvant chemotherapy. Results Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Women with low risk estimates from both the standard and genomic tests reported the lowest distress levels. Distress was higher predominately among patients who had received high genomic risk estimates, who did not receive genomic risk estimates, or who received conflicting estimates based on genomic and clinical criteria. Cancer worry was highest for patients with higher risk perceptions and lower satisfaction. Patients with concordant high-risk profiles and those for whom such profiles were not available reported lower quality of life. Conclusion Patients were generally satisfied with the information they received about recurrence risk based on genomic testing. Some types of genomic test results were associated with greater distress levels, but not with cancer worry or HRQoL. Trial registration ISRCTN: ISRCTN18543567
- Subjects :
- Adult
medicine.medical_specialty
Cancer Research
Health Knowledge, Attitudes, Practice
Genomic profile
Patient-centered care
media_common.quotation_subject
Decision Making
Breast Neoplasms
Disease
Risk Assessment
Breast cancer
Quality of life
METIS-296788
Internal medicine
Surveys and Questionnaires
Genetics
Medicine
Humans
Chemotherapy
media_common
Aged
Response rate (survey)
Gynecology
business.industry
Gene Expression Profiling
IR-86398
Cancer
Genomics
Middle Aged
medicine.disease
Prognosis
Personalized medicine
Distress
Oncology
Chemotherapy, Adjuvant
Quality of Life
Female
Lymph Nodes
70-gene signature
Worry
Neoplasm Recurrence, Local
business
Risk assessment
Research Article
Subjects
Details
- ISSN :
- 14712407
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- BMC cancer
- Accession number :
- edsair.doi.dedup.....bce0725c5315d14109db316c3cb6ec6f